Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Research & Development (2016 - 2025)

Sonoma Pharmaceuticals has reported Research & Development over the past 16 years, most recently at $557000.0 for Q4 2025.

  • For Q4 2025, Research & Development rose 30.44% year-over-year to $557000.0; the TTM value through Dec 2025 reached $2.1 million, up 17.94%, while the annual FY2025 figure was $1.8 million, 3.05% down from the prior year.
  • Research & Development for Q4 2025 was $557000.0 at Sonoma Pharmaceuticals, down from $575000.0 in the prior quarter.
  • Over five years, Research & Development peaked at $601000.0 in Q4 2023 and troughed at $4000.0 in Q1 2022.
  • A 5-year average of $330105.3 and a median of $409000.0 in 2024 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: plummeted 96.92% in 2022 and later skyrocketed 4925.0% in 2023.
  • Year by year, Research & Development stood at $26000.0 in 2021, then surged by 669.23% to $200000.0 in 2022, then soared by 200.5% to $601000.0 in 2023, then decreased by 28.95% to $427000.0 in 2024, then surged by 30.44% to $557000.0 in 2025.
  • Business Quant data shows Research & Development for SNOA at $557000.0 in Q4 2025, $575000.0 in Q3 2025, and $594000.0 in Q2 2025.